About illumina inc. - ILMN
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
ILMN At a Glance
Illumina, Inc.
5200 Illumina Way
San Diego, California 92122
| Phone | 1-858-202-4500 | Revenue | 4.34B | |
| Industry | Medical Specialties | Net Income | 850.00M | |
| Sector | Health Technology | Employees | 8,600 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ILMN Valuation
| P/E Current | 23.121 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 24.767 |
| Price to Sales Ratio | 4.853 |
| Price to Book Ratio | 7.583 |
| Price to Cash Flow Ratio | 19.51 |
| Enterprise Value to EBITDA | 19.376 |
| Enterprise Value to Sales | 5.065 |
| Total Debt to Enterprise Value | 0.116 |
ILMN Efficiency
| Revenue/Employee | 504,418.605 |
| Income Per Employee | 98,837.209 |
| Receivables Turnover | 4.913 |
| Total Asset Turnover | 0.67 |
ILMN Liquidity
| Current Ratio | 2.075 |
| Quick Ratio | 1.719 |
| Cash Ratio | 1.03 |
ILMN Profitability
| Gross Margin | 66.69 |
| Operating Margin | 19.917 |
| Pretax Margin | 25.035 |
| Net Margin | 19.594 |
| Return on Assets | 13.13 |
| Return on Equity | 33.359 |
| Return on Total Capital | 16.111 |
| Return on Invested Capital | 18.649 |
ILMN Capital Structure
| Total Debt to Total Equity | 93.757 |
| Total Debt to Total Capital | 48.389 |
| Total Debt to Total Assets | 38.426 |
| Long-Term Debt to Equity | 72.567 |
| Long-Term Debt to Total Capital | 37.453 |
Illumina Inc. in the News
What's happening with Trump's tariffs on China, Canada and Mexico?
President Donald Trump's tariff dispute with China, Canada and Mexico over fentanyl smuggling and illegal immigration has led to retaliation by the Chinese government.
Cancer test company says vendor mistakenly sent letters to 400 patients that they may have disease
Grail, Inc. said Friday that it erroneously sent out hundreds of form letters that mistakenly told patients they had cancer when many of them had not yet taken the blood test.